The main objective of this study is to evaluate outcomes of bladder preservation treatment for patients with muscle-invasive bladder cancer.
38 patients with histologically proven muscle-invasive bladder cancer treated at our department between January 2008 and December 2013 were analyzed retrospectively. Age, gender, pathology, stage, 3-year overall survival, 3-year disease-free survival, radiotherapy (RT) dose, genitourinary and gastrointestinal toxicity scores and response evaluation of the patients were recorded. 3-year overall survival and 3-year disease-free survivals were calculated by Kaplan-Meier method along with the analysis of gender, pathology, stage and therapy response of the study group.
33 patients (86.8%) were managed with concomitant chemoradiotherapy whereas 5 patients (13.2%) received only radiation therapy due to renal insufficency and comorbid diseases. 6 (15.8%) out of 38 patients had partial response (PR) and remaining 32 (84.2%) patients experienced complete response (CR). The PR group underwent salvage cystectomy and CR group had been followed-up after radical radiotherapy. Mean age of the group was 70.9 (range 45-90) years. 26 of all patients were male (68.4%) and 12 were female (31.6%). Mean follow-up time after completion of radiotherapy was 24.7 months (range 12-40). Mean RT dose was 64 Gy (range 60-66). 3-year overall survival was 64% and 3-year disease free survival was 73%.
Bladder preserving approach is an alternative definitive therapy solution to radical cystectomy in the treatment of muscle-invasive bladder cancer with less morbidity, preserved natural bladder, and high quality of life.
Tumori 2015; 101(2): 232 - 237
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsBora Uysal, Murat Beyzadeoglu, Selcuk Demiral, Hakan Gamsiz, Ferrat Dincoglan, Omer Sager, Mustafa Akin, Mustafa Alparslan Babayigit
- • Accepted on 14/02/2015
- • Available online on 09/03/2015
- • Published in print on 28/04/2015
This article is available as full text PDF.
- Uysal, Bora [PubMed] [Google Scholar] 1, * Corresponding Author (email@example.com)
- Beyzadeoglu, Murat [PubMed] [Google Scholar] 1
- Demiral, Selcuk [PubMed] [Google Scholar] 1
- Gamsiz, Hakan [PubMed] [Google Scholar] 1
- Dincoglan, Ferrat [PubMed] [Google Scholar] 1
- Sager, Omer [PubMed] [Google Scholar] 1
- Akin, Mustafa [PubMed] [Google Scholar] 1
- Babayigit, Mustafa Alparslan [PubMed] [Google Scholar] 2
Department of Radiation Oncology, Gulhane Military Medical Academy, Ankara - Turkey
Department of Public Health, Gulhane Military Medical Academy, Ankara - Turkey